Injective (INJ) is currently trading at $4.77, having experienced a significant decline of 8.03% over the past 24 hours. The price fluctuated within a daily range of $4.60 to $5.27, indicating a heightened volatility that investors should note.

Trading volume stands at approximately 76 million, reflecting a volume-to-market cap ratio of 15.94%, which suggests active trading interest but also potential for further price swings. The moving averages present a bearish outlook, with the 55 SMA at $5.16 and the 144 SMA at $5.29 indicating resistance levels that have not been tested positively in the current downtrend.

The 1-hour RSI at 27 signifies that INJ is approaching oversold territory, suggesting a potential rebound in the short term. However, the 7-day RSI of 42 indicates a lack of bullish momentum, reinforcing the notion of a continuing downward trend unless a strong catalyst emerges.

Over the last week, INJ has declined by 7.27%, with a more significant drop of 8.88% over the past 14 days. The 30-day price change is marginally negative at -0.30%, indicating that the asset has been under pressure but is stabilizing at a lower price point.

Given the all-time high of $52.62, the current price reflects a substantial depreciation, leading to concerns about investor confidence and future price recovery. The prevailing technical indicators and declining RSI suggest that INJ lacks the momentum necessary for an immediate turnaround.

In conclusion, the current data points to a bearish outlook for Injective (INJ) with limited near-term upside potential. Therefore, the recommendation is to Hold, allowing for potential stabilization or a clearer trend reversal before making any buying decisions.